NIH Cuts Back On New And Competitive Grants

Competition for research funds will heat up, but most scientists sat that NIH is making the right decision. WASHINGTON, D.C.--The National Institutes of Health have long struggled with a painful dilemma. Given finite dollars, how can a funding agency manage to reward proven investigators while still nurturing fresh talent? In recent years, NIH's answer has been to trim existing grants in order to fund more new scientists. But in a recent major change in policy, NIH has decided to sharply redu

Written byJeffrey Mervis
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

WASHINGTON, D.C.--The National Institutes of Health have long struggled with a painful dilemma. Given finite dollars, how can a funding agency manage to reward proven investigators while still nurturing fresh talent? In recent years, NIH's answer has been to trim existing grants in order to fund more new scientists. But in a recent major change in policy, NIH has decided to sharply reduce the number of new, competing grants - and use the money to boost existing awards.

The decision, predictably, is a mixed blessing for scientists. Joe Coulter of the University of Iowa, for example, whose current NIH grant had been cut by 10% in each of the past two years, may eventually be able to stop dipping into state funds to pay the stipends of two of his postdocs. Researchers like the University of Southern California's Willa Hsueh, however, will be facing stiffer competition for their grant applications. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies